Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
ABSTRACTThis study aimed to validate the prognostic value of Immunoscore (IS) in stage II colorectal cancer (CRC), and explore the roles of IS and circulating tumor DNA (ctDNA) in the adjuvant treatment for early-stage CRC. Resected tumor samples from stage II CRC patients were collected from the Su...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2161167 |
| _version_ | 1797367131516436480 |
|---|---|
| author | Fulong Wang Shixun Lu Di Cao Juanjuan Qian Cong Li Rongxin Zhang Feng Wang Miaoqing Wu Yifan Liu Zhizhong Pan Xiaojun Wu Zhenhai Lu Peirong Ding Liren Li Junzhong Lin Aurélie Catteau Jérôme Galon Gong Chen |
| author_facet | Fulong Wang Shixun Lu Di Cao Juanjuan Qian Cong Li Rongxin Zhang Feng Wang Miaoqing Wu Yifan Liu Zhizhong Pan Xiaojun Wu Zhenhai Lu Peirong Ding Liren Li Junzhong Lin Aurélie Catteau Jérôme Galon Gong Chen |
| author_sort | Fulong Wang |
| collection | DOAJ |
| description | ABSTRACTThis study aimed to validate the prognostic value of Immunoscore (IS) in stage II colorectal cancer (CRC), and explore the roles of IS and circulating tumor DNA (ctDNA) in the adjuvant treatment for early-stage CRC. Resected tumor samples from stage II CRC patients were collected from the Sun Yat-sen University Cancer Center. The densities of CD3+ and CD8+ lymphocytes were quantified and converted to IS and classified into Low, Intermediate (Int), and High groups according to predefined cutoffs. A total of 113 patients were included in the study. Patients with IS-High, Int, and Low were 43 (38%), 62 (55%), and 8 (7%), respectively. Patients with IS-High had an excellent clinical outcome, with none recurring during a median follow-up of 3 years, including 15 (35%) clinical high-risk patients. The 3-year disease-free survival (DFS) was 100% for IS-High, 76% for IS-Int, and 47% for IS-Low (P < .001). In the multivariate Cox analysis, IS was the only significant parameter associated with DFS. IS-Int and IS-Low patients with adjuvant chemotherapy had improved DFS compared to those who did not receive adjuvant chemotherapy (HR = 0.3; 95% CI 0.1–0.92; P = .026). Among the 49 patients with postoperative ctDNA data, IS-High patients had the lowest ctDNA positivity rate, suggesting that they were most eligible for chemotherapy-free treatment. IS had a strong prognostic value in Chinese patients with stage II CRC and demonstrates its clinical utility. IS and ctDNA will jointly optimize the adjuvant treatment strategies for early-stage CRC. |
| first_indexed | 2024-03-08T17:12:59Z |
| format | Article |
| id | doaj.art-89b95f1a4dbf4a6e976c2cbd1aeac50d |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-03-08T17:12:59Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-89b95f1a4dbf4a6e976c2cbd1aeac50d2024-01-03T19:25:36ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2022.2161167Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancerFulong Wang0Shixun Lu1Di Cao2Juanjuan Qian3Cong Li4Rongxin Zhang5Feng Wang6Miaoqing Wu7Yifan Liu8Zhizhong Pan9Xiaojun Wu10Zhenhai Lu11Peirong Ding12Liren Li13Junzhong Lin14Aurélie Catteau15Jérôme Galon16Gong Chen17Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Medicine, Genecast Biotechnology Co., Ltd, Beijing, ChinaDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaVeracyte, Marseille, FranceVeracyte, Marseille, FranceDepartment of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Hong Kong, ChinaABSTRACTThis study aimed to validate the prognostic value of Immunoscore (IS) in stage II colorectal cancer (CRC), and explore the roles of IS and circulating tumor DNA (ctDNA) in the adjuvant treatment for early-stage CRC. Resected tumor samples from stage II CRC patients were collected from the Sun Yat-sen University Cancer Center. The densities of CD3+ and CD8+ lymphocytes were quantified and converted to IS and classified into Low, Intermediate (Int), and High groups according to predefined cutoffs. A total of 113 patients were included in the study. Patients with IS-High, Int, and Low were 43 (38%), 62 (55%), and 8 (7%), respectively. Patients with IS-High had an excellent clinical outcome, with none recurring during a median follow-up of 3 years, including 15 (35%) clinical high-risk patients. The 3-year disease-free survival (DFS) was 100% for IS-High, 76% for IS-Int, and 47% for IS-Low (P < .001). In the multivariate Cox analysis, IS was the only significant parameter associated with DFS. IS-Int and IS-Low patients with adjuvant chemotherapy had improved DFS compared to those who did not receive adjuvant chemotherapy (HR = 0.3; 95% CI 0.1–0.92; P = .026). Among the 49 patients with postoperative ctDNA data, IS-High patients had the lowest ctDNA positivity rate, suggesting that they were most eligible for chemotherapy-free treatment. IS had a strong prognostic value in Chinese patients with stage II CRC and demonstrates its clinical utility. IS and ctDNA will jointly optimize the adjuvant treatment strategies for early-stage CRC.https://www.tandfonline.com/doi/10.1080/2162402X.2022.2161167Immunoscorecolorectal cancerprognosticpredictiveadjuvant chemotherapyctDNA |
| spellingShingle | Fulong Wang Shixun Lu Di Cao Juanjuan Qian Cong Li Rongxin Zhang Feng Wang Miaoqing Wu Yifan Liu Zhizhong Pan Xiaojun Wu Zhenhai Lu Peirong Ding Liren Li Junzhong Lin Aurélie Catteau Jérôme Galon Gong Chen Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer OncoImmunology Immunoscore colorectal cancer prognostic predictive adjuvant chemotherapy ctDNA |
| title | Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer |
| title_full | Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer |
| title_fullStr | Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer |
| title_full_unstemmed | Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer |
| title_short | Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer |
| title_sort | prognostic and predictive value of immunoscore and its correlation with ctdna in stage ii colorectal cancer |
| topic | Immunoscore colorectal cancer prognostic predictive adjuvant chemotherapy ctDNA |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2161167 |
| work_keys_str_mv | AT fulongwang prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT shixunlu prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT dicao prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT juanjuanqian prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT congli prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT rongxinzhang prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT fengwang prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT miaoqingwu prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT yifanliu prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT zhizhongpan prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT xiaojunwu prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT zhenhailu prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT peirongding prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT lirenli prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT junzhonglin prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT aureliecatteau prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT jeromegalon prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer AT gongchen prognosticandpredictivevalueofimmunoscoreanditscorrelationwithctdnainstageiicolorectalcancer |